NYSEMKT: VNRXVolitionrx Ltd Stock
$0.53+0.01 (+1.92%)
Updated Mar 27, 2025
VNRX Price
$0.53
Fair Value Price
N/A
Market Cap
$48.93M
52 Week Low
$0.43
52 Week High
$1.02
P/E
-1.47x
P/B
-2.28x
P/S
41.08x
PEG
N/A
Dividend Yield
N/A
Revenue
$1.29M
Earnings
-$29.87M
Gross Margin
100%
Operating Margin
-2,299.44%
Profit Margin
-2,323.2%
Debt to Equity
-1.64
Operating Cash Flow
-$14M
Beta
0.8
Next Earnings
May 12, 2025
Ex-Dividend
N/A
Next Dividend
N/A
VNRX Overview
VolitionRX Ltd. is a multi-national life sciences company, which engages in the development of blood-based cancer tests to help diagnose a range of cancers. The company is headquartered in Austin, Texas and currently employs 44 full-time employees. The firm is focused on developing blood-based diagnostic tests for detecting and diagnosing cancer and other diseases. The firm has developed approximately 30 blood-based assays to detect specific biomarkers that can be used individually or in combination to generate a profile, which forms the basis of a test for a particular cancer or disease. The firm's Nucleosomics biomarker platform is a technology that is used for a range of cancers. The firm is developing Nucleosomics tests for various cancers, including colorectal, pancreatic, lung and aggressive prostate. The firm's NuQ blood assays fall into over five types, which include NuQ-X, NuQ-V, NuQ-M, NuQ-A and NuQ-T. The company has developed approximately two blood assays in the NuQ-X family to detect the presence of cancer by detecting nucleosomes containing specific nucleotides.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine VNRX's potential to beat the market
- VNRX doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Be the first to know about important VNRX news, forecast changes, insider trades & much more!
VNRX News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how VNRX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
VNRX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
VNRX is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
VNRX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more VNRX due diligence checks available for Premium users.
Valuation
VNRX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.47x
Industry
43.89x
Market
31.08x
VNRX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-2.28x
Industry
3.73x
VNRX's financial health
Profit margin
Revenue
$474.5k
Net Income
-$5.8M
Profit Margin
-1,226.8%
VNRX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
VNRX's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$12.7M
Liabilities
$35.3M
Debt to equity
-1.64
VNRX's short-term liabilities ($30.28M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
VNRX's short-term assets ($6.80M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
VNRX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
VNRX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$5.4M
Investing
-$136.7k
Financing
$5.6M
VNRX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
VNRX vs Diagnostic & Research Stocks
Volitionrx Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.